Share on StockTwits

Eli Lilly and (NYSE:LLY) has earned an average recommendation of “Buy” from the twenty-two analysts that are presently covering the stock, Analyst Ratings Network.com reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $64.33.

A number of analysts have recently weighed in on LLY shares. Analysts at Deutsche Bank initiated coverage on shares of Eli Lilly and in a research note on Wednesday, August 27th. They set a “buy” rating and a $71.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Eli Lilly and from $65.00 to $61.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Finally, analysts at S&P Equity Research initiated coverage on shares of Eli Lilly and in a research note on Friday, August 1st. They set a “buy” rating on the stock.

Shares of Eli Lilly and (NYSE:LLY) opened at 63.56 on Thursday. Eli Lilly and has a 1-year low of $47.53 and a 1-year high of $65.70. The stock’s 50-day moving average is $62.2 and its 200-day moving average is $60.05. The company has a market cap of $68.117 billion and a price-to-earnings ratio of 20.04.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.68 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.65 by $0.03. The company had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.88 billion. During the same quarter last year, the company posted $1.16 earnings per share. Eli Lilly and’s revenue was down 16.8% compared to the same quarter last year. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.